The lab-on-chip device employs micro-fluidics technology and is capable of performing complex analyses using 90% less sample than needed in conventional tests.

Mehdi Ghodbane said, "The main advantage is cost. These assays are done in labs and clinics everywhere. A great deal of research has been hindered because in many cases one is not able to extract enough fluid."
Until now, animal research on central nervous system disorders, such as spinal cord injury and Parkinson's disease, has been limited because scientists were unable to extract sufficient cerebrospinal fluid to perform conventional assays. The authors said, "With our technology, researchers will be able to perform large-scale controlled studies with comparable accuracy to conventional assays."
This discovery could also lead to more comprehensive research on autoimmune joint disorders such as rheumatoid arthritis.
The results were published in Lab.
Source-IANS